There are 2789 resources available
1381P - Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
Presenter: Markus Moehler
Session: ePoster Display
1654P - A phase Ib/II study of the dual MDMX/MDM2 inhibitor, ALRN-6924, for the prevention of chemotherapy-induced myelosuppression
Presenter: Zoran Andric
Session: ePoster Display
1655P - Real-world outcome of patients with relapsed or refractory small cell lung cancer treated with checkpoint inhibitors in Tertiary Care Centers across Germany
Presenter: Jan Stratmann
Session: ePoster Display
1656P - Germline mutations in DNA damage repair genes in patients with small cell lung cancer
Presenter: Yu Feng
Session: ePoster Display
1657P - Anlotinib plus irinotecan or docetaxel in small-cell lung cancer (SCLC) relapsed within six months: Updated results from a single-arm phase II study
Presenter: Bing Xia
Session: ePoster Display
1658P - Clinical characteristics of long-term survivors (LTS) in small cell lung cancer (SCLC) patients (p) with extended disease (ED)
Presenter: Andrea Plaja
Session: ePoster Display
1659P - Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer
Presenter: Ning Yan
Session: ePoster Display
1660P - Changes in the pattern of diagnosis and treatment of patients with SCLC in the last 20 years
Presenter: Alejandro Rios Hoyo
Session: ePoster Display
1662P - Comprehensive analysis of the metabolic enzymes in patients with small cell lung cancer using a large-scale targeted proteomics assay
Presenter: Gouji Toyokawa
Session: ePoster Display